Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Sujan Shresta · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2022 · $712,699 — ABSTRACT The long-term goal of this project is to develop a dengue-Zika vaccine that provides protection against the four serotypes of dengue (DENV1-4) and Zika (ZIKV) viruses with maximal safety and efficacy. To date, flavivirus vaccine development has focused on the induction of neutralizing antib…
BALI PULENDRAN · STANFORD UNIVERSITY · 2022 · $2,168,222 — ABSTRACT – Overall Component In the current proposal we will use a systems vaccinology approach to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). Th…
Nicolas Wentzensen · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · 2022 · $705,297 — The following research projects are etiologic and human population based and all have various molecular components:SUCCEED directed by Dr. Wentzensen is a cross-sectional study among women referred for abnormal cevrical cancer screening results focused on the identification of biomarkers of risk at …
Malcolm Martin · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $2,004,520 — SEQUENTIAL IMMUNIZATION OF MACAQUES ELICITS HETEROLOGOUS NEUTRALIZING ANTIBODIES TARGETING THE V3-GLYCAN PATCH OF HIV-1 ENV. Broadly neutralizing antibodies (bNAbs) against HIV-1 develop after prolonged virus and antibody coevolution. Previous studies showed that sequential immunization with a V3-…
Lothar Hennighausen · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2022 · $2,134,432 — Objective 1 SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. We have conducted three clinical studies addressing newly emerging questions and problems as the pandemic progressed. Although a large percentage of infected individuals are asymptomatic, the r…
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2022 · $505,395 — A collection of human samples is being analyzed to examine in detail humoral and cellular immunity after natural infection. These patients recovered from infection and accepted to donate convalescent plasma for transfer to hospitalized patients in an approved clinical trial. The immun…
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $955,000 — Our previous work has led to the development of vaccines against respiratory syncytial virus and Zika that have reached late phase clinical testing. While we are still performing some exploratory studies on vaccine-elicited immunity following RSV vaccination, the work of the Respiratory Viruses Core…
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2022 · $884,441 — An important goal of this project continues to be the generation and testing of maximally efficient expression vectors for specific antigens. Our hypothesis is that the DNA vaccine dose is suboptimal for many human applications; therefore, increased efficiency is necessary for practic…
Christina Annunziata · DIVISION OF BASIC SCIENCES - NCI · 2022 · $605,550 — Goal 1: Monocytes It has been shown in mouse models of chemically induced cancer that Interferons (IFNs) are important in the immune-surveillance and immune-editing of tumors. While IFNs alpha (IFNa) and gamma (IFNg) have been shown to have potent anti-neoplastic and anti-proliferativ…
Scott Dexter Boyd · STANFORD UNIVERSITY · 2022 · $309,746 — ABSTRACT – Project 3 The focus of Project 3 is to study antigen-specific B cell and plasma cell responses in the context of two timely and fundamental topics in vaccinology: (i) Immunology of COVID-19 vaccines, and (ii) the impact of the microbiota on immune responses to vaccination. The COVID-19 pa…
Matthew Adrian Coleman · LAWRENCE LIVERMORE NATIONAL SECURITY, LLC · 2022 · $383,265 — ABSTRACT Throughout the world Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen. In countries with poor sanitary conditions ocular infections with Ct can result in trachoma, the most frequent cause of preventable blindness worldwide. Based on protection and serolo…
Thomas Denny · DUKE UNIVERSITY · 2022 · $6,432,773 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
Andrea Goldberg Edlow · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $470,797 — Project 1: Summary The COVID-19 pandemic has revolutionized our ability to decode the rules of maternal immunity. There is a significant gap in knowledge regarding innate and adaptive immune responses over the course of pregnancy and how trimester-specific perturbations in the maternal immunological…
Barton F. Haynes · DUKE UNIVERSITY · 2022 · $2,197,512 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $343,970 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
Benjamin L Miller · UNIVERSITY OF ROCHESTER · 2022 · $447,221 — Abstract The field of Osteoimmunology was established in 2005 to understand how bone influences immune and hematopoietic cells, as well as how hematopoietic and immune cells influence bone, in clinical conditions like osteomyelitis. However, several critical research tools and rigorously validated p…
aarthi talla · SEATTLE CHILDREN'S HOSPITAL · 2022 · $127,742 — HIPC3 Scientific Project 3: Immune response to SARS-CoV-2 natural infection followed by vaccination Abstract This project will characterize the innate and adaptive immune response to SARS-CoV-2 natural infection in the setting of mild disease and follow-on vaccination. We will define signatures corr…
Kai W Wucherpfennig · BRIGHAM AND WOMEN'S HOSPITAL · 2022 · $351,997 — Abstract T cells are central effector cells of protective anti-tumor immunity, but little is currently known about these important immune cells in human GBM. We have generated single-cell RNA-seq data on tumor-infiltrating T cell populations from GBM patients at initial diagnosis or relapse. We used…
GARRY P NOLAN · STANFORD UNIVERSITY · 2022 · $234,850 — PROJECT SUMMARY New technologies such as mass cytometry have greatly expanded our ability to deepen our understanding of the complexity of lymphocytes and related populations. The Stanford CCHI group has been particularly attuned to the potential in following the lead of the Nolan lab in exploiting …
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2022 · $220,445 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…